RegentAtlantic Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $2.18M | Buy |
35,350
+1,429
| +4% | +$90.1K | 0.07% | 200 |
|
|
2022
Q2 | $2.1M | Buy |
33,921
+538
| +2% | +$33.3K | 0.07% | 206 |
|
|
2022
Q1 | $1.99M | Sell |
33,383
-1,619
| -5% | -$103K | 0.06% | 224 |
|
|
2021
Q4 | $2.54M | Buy |
35,002
+876
| +3% | +$60.3K | 0.07% | 190 |
|
|
2021
Q3 | $2.38M | Buy |
34,126
+1,211
| +4% | +$85.1K | 0.07% | 183 |
|
|
2021
Q2 | $2.27M | Buy |
32,915
+930
| +3% | +$62.1K | 0.07% | 190 |
|
|
2021
Q1 | $2.07M | Buy |
31,985
+2,079
| +7% | +$134K | 0.07% | 186 |
|
|
2020
Q4 | $1.74M | Sell |
29,906
-21,479
| -42% | -$1.3M | 0.07% | 187 |
|
|
2020
Q3 | $3.25M | Sell |
51,385
-35,939
| -41% | -$2.49M | 0.15% | 123 |
|
|
2020
Q2 | $6.72M | Buy |
87,324
+45,410
| +108% | +$3.48M | 0.37% | 62 |
|
|
2020
Q1 | $3.13M | Buy |
41,914
+2,580
| +7% | +$178K | 0.24% | 97 |
|
|
2019
Q4 | $2.56M | Sell |
39,334
-9,168
| -19% | -$597K | 0.16% | 146 |
|
|
2019
Q3 | $3.07M | Buy |
48,502
+1,893
| +4% | +$124K | 0.2% | 124 |
|
|
2019
Q2 | $3.15M | Buy |
46,609
+4,013
| +9% | +$264K | 0.21% | 118 |
|
|
2019
Q1 | $2.77M | Buy |
42,596
+8,886
| +26% | +$591K | 0.19% | 121 |
|
|
2018
Q4 | $2.11M | Sell |
33,710
-10,205
| -23% | -$713K | 0.18% | 137 |
|
|
2018
Q3 | $3.39M | Sell |
43,915
-9,621
| -18% | -$727K | 0.26% | 102 |
|
|
2018
Q2 | $3.79M | Sell |
53,536
-6,282
| -11% | -$444K | 0.33% | 85 |
|
|
2018
Q1 | $4.51M | Buy |
59,818
+1,746
| +3% | +$139K | 0.38% | 76 |
|
|
2017
Q4 | $4.16M | Buy |
58,072
+3,147
| +6% | +$239K | 0.34% | 79 |
|
|
2017
Q3 | $4.45M | Buy |
54,925
+1,713
| +3% | +$131K | 0.39% | 72 |
|
|
2017
Q2 | $3.77M | Buy |
53,212
+1,198
| +2% | +$79.7K | 0.34% | 79 |
|
|
2017
Q1 | $3.53M | Buy |
52,014
+9,280
| +22% | +$653K | 0.33% | 81 |
|
|
2016
Q4 | $3.06M | Sell |
42,734
-15,531
| -27% | -$1.15M | 0.3% | 89 |
|
|
2016
Q3 | $4.61M | Buy |
58,265
+1,796
| +3% | +$146K | 0.48% | 58 |
|
|
2016
Q2 | $4.71M | Buy |
56,469
+8,773
| +18% | +$779K | 0.45% | 56 |
|
|
2016
Q1 | $4.38M | Sell |
47,696
-4,290
| -8% | -$387K | 0.48% | 50 |
|
|
2015
Q4 | $5.26M | Buy |
51,986
+25,870
| +99% | +$2.69M | 0.56% | 55 |
|
|
2015
Q3 | $2.56M | Buy |
26,116
+20,124
| +336% | +$2.24M | 0.25% | 102 |
|
|
2015
Q2 | $702K | Buy |
5,992
+169
| +3% | +$18.5K | 0.06% | 222 |
|
|
2015
Q1 | $571K | Buy |
5,823
+50
| +0.9% | +$5.08K | 0.05% | 233 |
|
|
2014
Q4 | $544K | Sell |
5,773
-790
| -12% | -$81.7K | 0.05% | 240 |
|
|
2014
Q3 | $699K | Buy |
6,563
+936
| +17% | +$91.7K | 0.07% | 214 |
|
|
2014
Q2 | $467K | Buy |
5,627
+2,546
| +83% | +$198K | 0.04% | 258 |
|
|
2014
Q1 | $218K | Buy |
3,081
+214
| +7% | +$16.8K | 0.02% | 326 |
|
|
2013
Q4 | $215K | Buy |
+2,867
| New | +$200K | 0.02% | 331 |
|
Other funds holding GILD
RegentAtlantic Capital's GILD Position: Q3 2022 in Review
RegentAtlantic Capital increased its Gilead Sciences (GILD) stake by 4.2% in Q3 2022, buying an estimated $90.1K and bringing the position to 35,350 shares worth $2.18M. The position accounts for 0.07% of the portfolio, ranked #200.
RegentAtlantic Capital first reported a position in GILD in Q4 2013 and has held it in 36 quarters since. The position peaked at $6.72M in Q2 2020. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.
- RegentAtlantic Capital held 35,350 shares of Gilead Sciences worth $2.18M as of Q3 2022.
- RegentAtlantic Capital bought 1,429 Gilead Sciences shares in Q3 2022, an estimated $90.1K.
- Gilead Sciences made up 0.07% of RegentAtlantic Capital's portfolio in Q3 2022, its #200 holding.
- RegentAtlantic Capital first reported a position in Gilead Sciences in Q4 2013 and has held it in 36 quarters since.
- RegentAtlantic Capital's Gilead Sciences position peaked at $6.72M in Q2 2020.
- 1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.